|
WO2008018795A1
(en)
|
2006-08-11 |
2008-02-14 |
Prosensa Technologies B.V. |
Methods and means for treating dna repeat instability associated genetic disorders
|
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
KR20180105730A
(ko)
|
2010-07-19 |
2018-09-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
US8569254B2
(en)
|
2010-12-10 |
2013-10-29 |
National Yang Ming University |
Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
|
|
WO2012144906A1
(en)
*
|
2011-04-22 |
2012-10-26 |
Prosensa Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
|
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
US20140378533A1
(en)
|
2012-02-08 |
2014-12-25 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
BR112014026285B1
(pt)
|
2012-04-23 |
2021-08-31 |
Biomarin Technologies B.V |
Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares
|
|
EP2850188A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
|
|
WO2013173638A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
JP2015518712A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Ｍｅｃｐ２発現を調節するための組成物及び方法
|
|
JP2015518713A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Ｕｔｒｎ発現を調節するための組成物及び方法
|
|
US10029916B2
(en)
|
2012-06-22 |
2018-07-24 |
C3Nano Inc. |
Metal nanowire networks and transparent conductive material
|
|
EP3608407A1
(en)
|
2012-07-03 |
2020-02-12 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
WO2014011053A1
(en)
|
2012-07-12 |
2014-01-16 |
Proqr Therapeutics B.V. |
Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
|
|
US10020807B2
(en)
|
2013-02-26 |
2018-07-10 |
C3Nano Inc. |
Fused metal nanostructured networks, fusing solutions with reducing agents and methods for forming metal networks
|
|
EP3730614A3
(en)
*
|
2013-07-02 |
2020-12-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
|
WO2015017675A2
(en)
*
|
2013-07-31 |
2015-02-05 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
TW201536329A
(zh)
*
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
WO2015143246A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
KR20180030461A
(ko)
|
2015-05-29 |
2018-03-23 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
연장된 뉴클레오타이드 반복을 포함하는 유전자의 유해 영향 감소를 위한 뉴클레오사이드 제제
|
|
EP3334731B1
(en)
*
|
2015-08-14 |
2021-03-03 |
Merck Patent GmbH |
Phenoxazine derivatives for organic electroluminescent devices
|
|
CN108697709A
(zh)
|
2015-12-10 |
2018-10-23 |
Ptc医疗公司 |
用于治疗亨廷顿病的方法
|
|
EP3397288A4
(en)
|
2015-12-31 |
2019-09-11 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING ATAXIN-2 EXPRESSION
|
|
KR20230175312A
(ko)
|
2016-07-05 |
2023-12-29 |
바이오마린 테크놀로지스 비.브이. |
유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
|
|
JOP20190104A1
(ar)
*
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
ES3038159T3
(en)
|
2016-11-16 |
2025-10-09 |
Academisch Ziekenhuis Leiden |
Substances for targeting various selected organs or tissues
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
EP3565894A1
(en)
|
2017-01-03 |
2019-11-13 |
Zain-Luqman, Rula |
Therapeutic method for huntington's disease
|
|
AU2018282154B2
(en)
|
2017-06-05 |
2022-04-07 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
CN111182898B
(zh)
|
2017-06-28 |
2024-04-16 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
BR112020019373A2
(pt)
|
2018-03-27 |
2020-12-29 |
Ptc Therapeutics, Inc. |
Compostos para o tratamento da doença de hutington
|
|
WO2020005877A1
(en)
|
2018-06-27 |
2020-01-02 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
IL279688B2
(en)
|
2018-06-27 |
2025-01-01 |
Ptc Therapeutics Inc |
Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
|
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
|
WO2020089325A1
(en)
|
2018-11-02 |
2020-05-07 |
Biomarin Technologies B.V. |
Bispecific antisense oligonucleotides for dystrophin exon skipping
|
|
JP2023500251A
(ja)
|
2019-11-01 |
2023-01-05 |
ノバルティス アーゲー |
ハンチントン病の進行を遅らせる処置のためのスプライシングモジュレーターの使用
|
|
AU2021354760A1
(en)
|
2020-09-30 |
2023-05-11 |
Biomarin Technologies B.V. |
Antisense oligonucleotides targeting the exon 51 of dystrophin gene
|
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
TW202448485A
(zh)
|
2023-05-05 |
2024-12-16 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|